Managing Director & Partner
Emily Serazin joined Boston Consulting Group in 2006. She has been based both in the Washington and Mumbai offices. Emily is a core member of BCG’s Health Care and Social Impact practices. Within health care, Emily’s focus is on vaccines and global health across the value chain. She also has expertise in digital health and in the formation and optimization of public-private partnerships.
Examples of Emily's experience in the commercial health care sector include developing growth and product launch strategies for players in the global vaccines market, leading due diligences, and supporting post-merger integrations. In the realm of global public health, Emily has worked across leading global health institutions such as Gavi, UNICEF, WHO, and the Bill & Melinda Gates foundation to define investment strategies, coordinate multistakeholder efforts, prioritize portfolios, and identify key levers to drive uptake in low- and middle-income countries.
COVID-19 offered valuable lessons in combating epidemic-level disease. Four measures can help institutionalize what we’ve learned.
Stakeholder support is crucial for ensuring that African vaccine-manufacturing companies can produce sufficient supply for the continent.
The pandemic has exposed weaknesses in countries' health systems. Mid- to long-term planning for vaccines and beyond is necessary as the world moves toward controlling a virus that will be endemic.
Antimicrobial resistance is difficult to combat. This report gives a comprehensive assessment of vaccine R&D potential against pathogens with high levels of AMR.
COVID-19 will likely become endemic. If so, a global surveillance, treatment and vaccination infrastructure for monitoring and responding to outbreaks must be developed now.
Protecting the health-vulnerable population first can shave months off a country’s reopening.
Governments cannot let the most vulnerable be the least protected again. Countries, regions, and states can still get the rollout right through science, hard work, and vigilance.
A 12- to 18-month timeline assumes that a vaccine progresses through all the various stages of testing without encountering significant issues.
The humble toilet is undergoing a transformation, unlocking a vast new opportunity—not just to capture value but also to change lives.
Commercial applications are poised to go mainstream. Pharma and medtech companies, payers, and providers need to engage with the technology now.
In an op-ed for the Wall Street Journal, health experts from Harvard and BCG examine the causes and consequences of parents’ concerns about vaccine safety.